UroGen Pharma Ltd.
UroGen Pharma Ltd. (URGN): 8 pipeline candidates · 5 upcoming catalysts · ~11 mo cash runway · 4 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
11.1 months
D/E -3.04 · 0% dilution
Lead: Approved
8 candidates
5 upcoming, next in ~75d
0 buys · 8 sells (180d)
A transparent, data-derived signal for UroGen Pharma Ltd.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$1.5B
Cash
$110.0M
Quarterly Burn
$45.3M
Runway
11.1 mo
Revenue
$51.0M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (8 candidates)
Upcoming Catalysts (5)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
169
Total value held
$708.0M
| Holder | Shares | Value |
|---|---|---|
| rtw investments, lp | 4,543,895 | $81.7M |
| blackrock, inc. | 2,845,567 | $51.2M |
| toronto dominion bank | 2,616,714 | $47.0M |
| morgan stanley | 2,560,038 | $46.0M |
| acorn capital advisors, llc | 1,673,420 | $30.1M |
| american century companies inc | 1,637,570 | $29.4M |
| silverarc capital management, llc | 1,503,045 | $27.0M |
| opaleye management inc. | 1,430,000 | $25.7M |
| frontier capital management co llc | 1,314,112 | $23.6M |
| menora mivtachim holdings ltd. | 1,152,531 | $20.7M |
Showing top 10 of 169 institutional holders of UroGen Pharma Ltd.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in UroGen Pharma Ltd.'s pipeline?
UroGen Pharma Ltd. (URGN) has 8 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is UroGen Pharma Ltd.'s lead drug candidate?
UroGen Pharma Ltd.'s most advanced tracked candidate is jelmyto (Approved) for low-grade upper tract urothelial cancer.
What is UroGen Pharma Ltd.'s next catalyst?
UroGen Pharma Ltd.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3, Single-arm, Multicenter Study to Evaluate the Efficacy and Safety of UGN-103, a Novel For" — expected September 1, 2026.
What is UroGen Pharma Ltd.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, UroGen Pharma Ltd. has approximately 11.1 months of cash runway.
What is UroGen Pharma Ltd.'s market capitalization?
UroGen Pharma Ltd.'s market capitalization is approximately $1.5B.
Get the full picture on UroGen Pharma Ltd.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.